

ABSTRACT OF THE DISCLOSURE

The present invention provides pharmaceutical compositions and novel compounds useful in the treatment of conditions mediated by CCR2, MCP-1 or the interaction thereof.

- 5 The compounds of the present invention are pyrrolidinones and pyrrolidine-thiones.